Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
758
¥ millionWording
Definitive
How definitive the wording is.Recognition of an extraordinary loss
Subject Entity
綿半トレーディング株式会社 (the Company's consolidated subsidiary)
Target Locations / Products
Certain active pharmaceutical ingredients manufactured by 綿半トレーディング株式会社
This disclosure05/11/2026
Cause
Certain active pharmaceutical ingredients failed to meet standards.
Amount of Impact on Business Performance
¥758 million (valuation loss on the relevant products, recognized as an extraordinary loss)
Accounting period in which recognized
Fiscal year ending March 2026
Impact on Earnings Forecast
Reflected in the Summary of Financial Results for the Fiscal Year Ended March 2026 [Japanese GAAP] (Consolidated), released today
| Item | Details |
|---|---|
| Event name | Recognition of an extraordinary loss |
| Subject Entity | 綿半トレーディング株式会社 (the Company's consolidated subsidiary) |
| Target Locations / Products | Certain active pharmaceutical ingredients manufactured by 綿半トレーディング株式会社 |
| Cause | Certain active pharmaceutical ingredients failed to meet standards. |
| Amount of Impact on Business Performance | ¥758 million (valuation loss on the relevant products, recognized as an extraordinary loss) |
| Accounting period in which recognized | Fiscal year ending March 2026 |
| Impact on Earnings Forecast | Reflected in the Summary of Financial Results for the Fiscal Year Ended March 2026 [Japanese GAAP] (Consolidated), released today |
Items this document does not state (18)
Date of occurrenceDate recognized / date notice receivedType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changeOutlookPlanned follow-up disclosure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because certain active pharmaceutical ingredients manufactured by 綿半トレーディング株式会社 failed to meet standards.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.